Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive a ...

Fulcrum Therapeutics (NasdaqGM:FULC) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Company ParticipantsAlex C. Sapir - President and CEOCorinne Johnson - VPGregory Renza - Managing DirectorIain Fraser - SVP of Early DevelopmentJames Condulis - VP of Biotechnology Equity ResearchMartin Steinberg - Professor of Medicine, Pediatrics, Pathology, and Laboratory MedicineMatthew Biegler - Managing DirectorConference Call ParticipantsAnupam Rama - Managing Director and Senior Equity AnalystJoseph Schwartz - M ...

Fulcrum Therapeutics (NasdaqGM:FULC) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Company ParticipantsAlex C. Sapir - President and CEOCorinne Johnson - VPGregory Renza - Managing DirectorIain Fraser - SVP of Early DevelopmentJames Condulis - VP of Biotechnology Equity ResearchMartin Steinberg - Professor of Medicine, Pediatrics, Pathology, and Laboratory MedicineMatthew Biegler - Managing DirectorConference Call ParticipantsAnupam Rama - Managing Director and Senior Equity AnalystJoseph Schwartz - M ...

Fulcrum Therapeutics (NasdaqGM:FULC) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Speaker10Good morning, and welcome to Fulcrum Therapeutics' conference call to discuss 12-week data from the 20-milligram cohort of the phase 1b PIONEER trial of pociredir and sickle cell disease. Currently, all participants are in a listen-only mode. This call is being webcast live and can be accessed on the Investors section of Fulcrum's website at www.fulcrumtx.com, where a replay will be available. I'll now turn the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38978 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 47-4839948 (State or other jurisdict ...

― Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― 20 mg cohort demonstrated rapid and robust fetal hemoglobin (HbF) induction, with mean absolute HbF increasing by 12.2% from a baseline of 7.1% to 19.3% at Week 12, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive crisis (VOC) reduction ― ― Fulcrum plans to initiate a potential registration-enabling trial in the second half of 20 ...

― Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically relevant response, with progression toward pan-cellular HbF induction as F-cells increased from 31% to 63% ― ― 7 of 12 patients (58%) achieved absolute HbF levels ≥20%; all patients achieved at least a 6.5% absolute increase in HbF ― ― Improvements in markers of hemolysis, improved erythropoiesis, and a >1 g/dL increase in total hemoglobin ― ― 7 of 12 patients (58%) ...

Company Overview - Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, particularly in areas of high unmet medical need [4] - The company's lead clinical program is pociredir, designed to increase fetal hemoglobin expression for the treatment of sickle cell disease (SCD) [4] Clinical Development - Fulcrum will present 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease on February 24, 2026 [1] - Pociredir is an investigational oral small-molecule inhibitor of Embryonic Ectoderm Development (EED), leading to downregulation of fetal globin repressors and increased fetal hemoglobin [5] - In the PIONEER trial, pociredir has shown dose-dependent increases in fetal hemoglobin, improvements in markers of hemolysis and anemia, and has been generally well-tolerated with no serious adverse events reported [5] Expert Involvement - Dr. Martin Steinberg, a prominent hematologist with extensive research on sickle cell disease, will join Fulcrum management for the conference call [2][3] - Dr. Steinberg has published over 450 articles and has contributed significantly to understanding the genetic basis and pathophysiology of sickle cell disease [3] Regulatory Status - Pociredir has received Fast Track and Orphan Drug Designation from the FDA for the treatment of sickle cell disease [5] Disease Background - Sickle cell disease is a genetic disorder caused by a mutation in the HBB gene, leading to inefficient oxygen transport and sickle-shaped red blood cells, which can cause various serious health complications [6]

Core Viewpoint - Fulcrum Therapeutics, Inc. (FULC) has seen a 4.9% increase in share price over the past month, closing at $10.87, with analysts suggesting a potential upside of 75.7% based on a mean price target of $19.1 [1] Price Targets and Analyst Estimates - The mean estimate consists of 10 short-term price targets with a standard deviation of $6.51, indicating variability in analyst predictions; the lowest estimate is $7.00 (35.6% decline), while the highest is $25.00 (130% increase) [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about FULC's earnings prospects, with a consensus indicating higher EPS estimates, which historically correlates with stock price movements [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 0.8%, with one estimate increasing and no negative revisions [12] - FULC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While price targets are commonly referenced by investors, they can often mislead; empirical research shows that they do not reliably predict actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Fulcrum Therapeutics is focused on developing oral small molecules aimed at modifying gene expression for rare diseases, with a current emphasis on sickle cell disease and their lead asset, pociredir, which is a fetal hemoglobin inducer [4]. Group 1: Company Overview - Fulcrum Therapeutics is led by CEO Alex Sapir, who expressed gratitude for the support from JPMorgan and highlighted the quality of their recent report [2]. - The company’s strategic focus is on addressing high unmet needs in rare diseases, particularly in benign hematology [4]. Group 2: Product Focus - The lead product, pociredir, is designed to induce fetal hemoglobin, which is expected to be a best-in-class treatment for sickle cell disease [4].